Cibc World Markets Corp Has $2.20 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Cibc World Markets Corp lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,886 shares of the company’s stock after selling 687 shares during the period. Cibc World Markets Corp’s holdings in Moderna were worth $2,199,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB increased its holdings in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new stake in shares of Moderna in the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC increased its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after acquiring an additional 388 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Down 2.6 %

MRNA opened at $32.45 on Friday. The stock has a market capitalization of $12.52 billion, a P/E ratio of -3.50 and a beta of 1.86. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The firm’s fifty day simple moving average is $35.10 and its 200 day simple moving average is $46.36.

Analysts Set New Price Targets

A number of research firms have commented on MRNA. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Berenberg Bank lifted their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Morgan Stanley lowered their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. UBS Group lowered their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Finally, The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $59.60.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.